Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
A quick guide helps you compare 401(k) options for your 30s, focusing on fees, employer matches, and potential tax outcomes.
24,750 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Bitcoin on-chain signals from Glassnode show a shift toward loss-dominant selling, with key metrics dipping below bea...
Oneok beat quarterly expectations but issued soft 2026 guidance, sending shares lower. This article explains why oneo...
Gate Technology has secured a Malta PSD2 Payment Institution license, strengthening EU payment rails for stablecoins ...
The bitcoin price rally riding on record U.S. margin debt has traders on edge. Analysts warn a swift unwind could arr...
Investors chasing reliable profits often look for markets with strong rent demand and balanced growth. This article b...
Geopolitical turmoil and potential chokepoint disruptions raise the odds of a renewed oil shock. Markets bracing $100...
Snowflake has delivered strong results, yet the stock has pulled back. This guide explains what snowflake shows signs...
SOL Strategies' shares jumped about 20% after it disclosed February validator network growth to 33,568 wallets. The m...
What could drive Entravision's 2025 earnings, and what should investors watch next? This guide breaks down the driver...
Gen Alpha now commands a growing slice of the U.S. wallet, with direct spending power crossing the $112 billion mark ...
Newrez is rolling out TitlePass in its wholesale channel, allowing brokers to waive the lender title insurance on cer...